Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. As a leader in the infectious disease field, we are highly committed to advancing new therapies for patients with serious infections. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.
Talented Team of People with a Mission to Save Lives
Spero has been named one of the 2020 Best Places to Work by the Boston Business Journal.
-
Tebipenem HBr
Oral Candidate to Treat MDR Gram-Negative Infections
Novel antibiotic with the potential to be the first oral carbapenem for use in adults to treat complicated urinary tract infection and acute pyelonephritis.
-
SPR720
Oral Candidate to Treat Non-tuberculous Mycobacterial Disease
Novel agent with the potential to be the first oral antibiotic specifically approved for the treatment of NTM disease.
- Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
- Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
- Spero Therapeutics Added to the NASDAQ Biotechnology Index
- Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
-
Investors
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities > -
Careers
Join a passionate team that pushes the limits in finding innovative therapies to help patients.
Career opportunities > -
Partners
Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >
